Sapna P. Patel

Also affiliated with University of Colorado Hospital, The University of Texas MD Anderson Cancer Center, University of Colorado Boulder, University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, JSS Dental College and Hospital, University of Colorado Denver

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 39 papers. Top paper: “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma”.

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New England Journal of Medicine(2023)10.1056/nejmoa2211437

N/A

6.5DataRank · unranked

846 citations

Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom +48 more

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02498-y

N/A

4.8DataRank · unranked

171 citations

Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia +28 more

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

Annals of Oncology(2020)10.1016/j.annonc.2020.04.471

N/A

3.5DataRank · unranked

110 citations

Alexander N. Shoushtari, D Chauhan, David Palmieri, Belinda Lee, Maartje W. Rohaan +20 more

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Nature Medicine(2023)10.1038/s41591-022-02170-x

N/A

1.9DataRank · unranked

83 citations

Sherise D. Ferguson, Roland L. Bassett, Alexandra P. Foster, Ida John, Tarin Hennegan +32 more

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

Science(2018)10.1126/science.aan4236

N/A

1.3DataRank · unranked

4585 citations

C. N. Spencer, Luigi Nezi, Alexandre Reuben, Miles C. Andrews, Tatiana V. Karpinets +89 more

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9501

N/A

1.3DataRank · unranked

18 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella +15 more

B cells and tertiary lymphoid structures promote immunotherapy response

Nature(2020)10.1038/s41586-019-1922-8

N/A

1.2DataRank · unranked

2719 citations

Sangeetha M. Reddy, Jianjun Gao, Shaojun Zhang, Rafet Başar, Rohit Thakur +55 more

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Cancer Discovery(2016)10.1158/2159-8290.cd-15-1545

N/A

1.0DataRank · unranked

1012 citations

Whijae Roh, Alexandre Reuben, Zachary A. Cooper, Christine N. Spencer, Peter A. Prieto +39 more

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Nature Medicine(2021)10.1038/s41591-021-01406-6

N/A

0.910DataRank · unranked

429 citations

Connie P. M. Duong, Vancheswaran Gopalakrishnan, Valerio Iebba, W. S. Chen, Lisa Derosa +66 more

Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit

Cancer(2021)10.1002/cncr.34004

N/A

0.890DataRank · unranked

21 citations

Sahira Farooq, Macartney Welborn, Rodabe N. Amaria, Susan Y. Chon, Adi Diab +13 more

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Nature(2022)10.1038/s41586-022-05368-8

N/A

0.874DataRank · unranked

339 citations

Michael A. Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos A. Torres‐Cabala +35 more

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Nature(2022)10.1038/s41586-022-04833-8

N/A

0.731DataRank · unranked

130 citations

Michael G. White, Miles C. Andrews, Manoj Chelvanambi, Russell G. Witt, Joseph R. Daniele +60 more

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Nature Communications(2022)10.1038/s41467-022-29539-3

N/A

0.716DataRank · unranked

117 citations

Yanshuo Chu, Mercy Misoi, María E. Suarez‐Almazor, Jean Tayar, Huifang Lu +33 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0.700DataRank · unranked

105 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000960

N/A

0.619DataRank · unranked

61 citations

Kathryn Bollin, Mariana Petaccia de Macêdo, Fernando C. L. Carapeto, Kevin B. Kim, Jason Roszik +12 more

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002449

N/A

0.574DataRank · unranked

45 citations

Rodabe N. Amaria, Amer Najjar, Laszlo Radvanyi, Cara Haymaker, Marie-Andrée Forget +18 more

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

British Journal of Cancer(2021)10.1038/s41416-020-01230-8

N/A

0.568DataRank · unranked

43 citations

Filip Jankú, Vivek Subbiah, John Stewart, Sapna P. Patel, Ahmed O. Kaseb +10 more

Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

Cancer(2024)10.1002/cncr.35587

N/A

0.539DataRank · unranked

9 citations

James Moon, T. Vincent, John P. Fruehauf, Lawrence E. Flaherty, Martin J. Bury +8 more

Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-1060

N/A

0.434DataRank · unranked

17 citations

Yuzhong Jeff Meng, Marie‐Andrée Forget, Tatiana V. Karpinets, Katarzyna Tomczak, Chip Stewart +22 more

Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma

British Journal of Cancer(2024)10.1038/s41416-024-02866-6

N/A

0.385DataRank · unranked

12 citations

Jason Roszik, Rajat Bhattacharya, Md Alauddin, Iqbal Mahmud, Sirisha Yadugiri +12 more

Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients

Cancers(2021)10.3390/cancers13133292

N/A

0.360DataRank · unranked

10 citations

Elizabeth Urias, Stephen K. Gruschkus, Michelle D. Williams, Maura S. Glover, Yong Qin +3 more

Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9513

N/A

0.350DataRank · unranked

6 citations

Marie‐Andrée Forget, Firas Kreidieh, Meredith Pelster, Michael A. Davies, Rodabe N. Amaria +3 more

Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma

OncoImmunology(2025)10.1080/2162402x.2025.2546402

N/A

0.323DataRank · unranked

7 citations

Simin Kiany, Marie‐Andrée Forget, Roland L. Bassett, Michael A. Davies, Adi Diab +15 more

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma

OncoImmunology(2021)10.1080/2162402x.2021.1984059

N/A

0.312DataRank · unranked

7 citations

Denái R. Milton, William H. Sharfman, Bret Taback, Lee D. Cranmer, Gregory A. Daniels +9 more

S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps9585

N/A

0.208DataRank · unranked

3 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +9 more

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Nature(2023)10.1038/s41586-023-05892-1

N/A

0.165DataRank · unranked

2 citations

Michael A. Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos A. Torres‐Cabala +35 more

Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial

Journal of Immunotherapy and Precision Oncology(2025)10.36401/jipo-24-10

N/A

0.165DataRank · unranked

2 citations

Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar A. Gurses, Ashabari Sprenger +6 more

Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.01.12.575058

N/A

0.104DataRank · unranked

1 citations

Jason Roszik, Rajat Bhattacharya, Md Alauddin, Iqbal Mahmud, Sirisha Yadugiri +11 more

S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps10090

N/A

0.104DataRank · unranked

1 citations

Megan Othus, James Moon, Michael T. Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak +8 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapy

Research Square(2020)10.21203/rs.3.rs-58480/v1

N/A

0DataRank · unranked

0 citations

Christopher P. Vellano, Michael White, Miles C. Andrews, Joseph R. Daniele, Mark Titus +41 more

1073P Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1458

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Megan Othus, Amy K. Darke, Ahmad A. Tarhini, John M. Kirkwood +5 more

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3138

N/A

0DataRank · unranked

0 citations

Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert +12 more

Successful tumor-infiltrating lymphocyte (TIL) growth from uveal melanoma (UM) using a three-signal (3.0) method.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3027

N/A

0DataRank · unranked

0 citations

Marie‐Andrée Forget, Stephen K. Gruschkus, Cara Haymaker, Chantale Bernatchez, Patrick Hwu +4 more

Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001800

N/A

0DataRank · unranked

131 citations

Malea Williams, K. Dixon, Crystal Dupuis, Amanda McWatters, Rony Avritscher +13 more

A phase Ib study of endogenous SLC45A2-specific cytotoxic T cells for the treatment of patients with metastatic uveal melanoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps10086

N/A

0DataRank · unranked

4 citations

Gregory Lizée, Courtney Brown, Jacqueline Lara, Roland L. Bassett, Lisa G Beal +8 more

Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma

Cancers(2023)10.3390/cancers15143630

N/A

0DataRank · unranked

7 citations

Sridevi Addanki, Yi‐Ju Chiang, Salyna Meas, Vanessa N. Sarli, Joshua Upshaw +6 more

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps9603

N/A

0DataRank · unranked

7 citations

James Moon, Yana G. Najjar, Rupesh Kotecha, Vadim Spektor, Michael C. Wu +6 more

Immune-related adverse events and symptom burden in patients with melanoma receiving adjuvant immune checkpoint inhibitor.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps12147

N/A

0DataRank · unranked

0 citations

Teresa Kuś, Salah-Eddine Bentebibel, Jennifer L. McQuade, Isabella Claudia Glitza, Rodabe N. Amaria +11 more